antifungal resistance – Page 20

qPCR-Based Molecular Detection of Trichophyton indotineae by Targeting Divergent Sequences

mycolabadmin

Trichophyton indotineae is a dangerous fungal infection that causes ringworm and is increasingly resistant to common antifungal treatments. Scientists developed a rapid blood test-like diagnostic tool called qPCR that can accurately identify this specific fungus in less than 2 hours for just a few dollars. The test was created by comparing the genetic codes of different fungal species to find unique fingerprints that distinguish T. indotineae from similar-looking fungi.

Antifungal stewardship in the UK: where are we now?

mycolabadmin

This paper examines how well the UK is currently managing antifungal stewardship—the appropriate use of antifungal medications to treat serious fungal infections while preventing resistance. Experts found that since 2017, progress has been limited due to lack of funding and staff expertise, difficulties accessing timely fungal diagnostic tests, and disruptions from the COVID-19 pandemic. The panel recommends creating regional mycology networks and diagnostic centres, establishing national standards for antifungal practices, and improving education about fungal infections to better prepare the UK for rising fungal disease threats.

Exposure to Tebuconazole Drives Cross-Resistance to Clinical Triazoles in Aspergillus fumigatus

mycolabadmin

Farmers use a fungicide called tebuconazole to protect crops, but this chemical is similar to medicines doctors use to treat serious fungal infections in patients. A new study shows that when the fungus Aspergillus fumigatus is exposed to tebuconazole, it becomes resistant not just to this pesticide, but also to the clinical antifungal drugs used in hospitals. The fungus develops resistance mechanisms that allow it to survive high doses of these medications. This research highlights an important public health concern: the overuse of similar chemicals in agriculture can undermine our ability to treat dangerous fungal infections in people.

Identification of Non-fumigatus Aspergillus Species in Clinical Samples from Southern California

mycolabadmin

Researchers in Southern California studied fungal infections caused by Aspergillus, a common mold that can infect humans. They found that species other than the traditionally dangerous A. fumigatus are now being detected more frequently in patient samples, particularly from skin and respiratory infections. These non-fumigatus species showed interesting seasonal patterns and some may be resistant to standard antifungal treatments, suggesting doctors may need to adjust their treatment strategies.

Addressing filamentous fungi-related onychomycosis in the era of antifungal resistance: assessment of Zataria multiflora nanostructured lipid carrier topical gel in a double-blinded clinical trial

mycolabadmin

Nail fungal infections (onychomycosis) are difficult to treat, especially as fungi become resistant to standard antifungal medications. Researchers tested a new gel made from Zataria multiflora (Shirazi thyme) packaged in special nanoparticles that help the medicine penetrate the nail better. In a clinical trial comparing this gel to placebo, the Zataria multiflora treatment showed better results after just 2 weeks, with 70% of patients experiencing fungal cure compared to 55% with placebo.

Increasing postgraduate medical mycology research dissertations at Uganda’s higher institution of learning

mycolabadmin

A study from Makerere University in Uganda found that funding has significantly boosted research on fungal diseases among graduate students. The number of students focusing on medical mycology jumped from 16% to 40% between 2023 and 2024, with more advanced laboratory techniques being used. The research focused on serious fungal infections like cryptococcal meningitis, which particularly affects people with HIV/AIDS. The university’s creation of a collaborative research group helped students work together and complete their projects on time.

First report of infections due to Candidozyma (formerly Candida) auris in Botswana, 2022–2024

mycolabadmin

Researchers in Botswana discovered the first documented cases of a dangerous fungal infection called Candidozyma auris in their country. This yeast was found in 10 patients at a major hospital, mostly in intensive care units, between 2022 and 2024. The fungus was resistant to common antifungal drugs like fluconazole but could still be treated with other medications. The findings highlight how this emerging pathogen is spreading across Africa and stress the importance of improved laboratory testing and disease monitoring in developing countries.

Tracing the Origin and Evolution of the Fungal Mycophenolic Acid Biosynthesis Pathway

mycolabadmin

Scientists studied how different fungal species produce mycophenolic acid, a drug used to prevent transplant rejection in millions of patients worldwide. By analyzing the genomes of many fungal species, they found that only a few fungi can make this important drug, and they discovered that these fungi have different ways of protecting themselves from being poisoned by their own medicine. This research helps us understand how fungi evolve to produce valuable medicines and could lead to better ways to produce immunosuppressants.

Virulence factors of Candida spp. isolated from COVID-19 patients: hydrolytic enzyme activity and biofilm formation

mycolabadmin

During the COVID-19 pandemic, many hospitalized patients developed fungal infections caused by Candida yeasts alongside their coronavirus infection. Researchers studied 71 Candida samples from COVID-19 patients to understand how these fungi cause disease by examining three damaging enzymes they produce and their ability to form protective biofilm layers. The findings showed that these fungi are highly virulent, producing strong enzyme activity that helps them invade tissues and resist treatment, which helps explain why these infections are particularly dangerous in COVID-19 patients.

Persistent Candidemia: Predictors and Outcomes in a Multicenter Matched Analysis

mycolabadmin

This study examined cases where fungal infections caused by Candida persisted in the bloodstream even after starting antifungal treatment. Researchers compared 46 patients with persistent infections to 92 control patients without persistent infections across three major medical centers. Patients with persistent candidemia were younger, more likely to be female, had more health complications, and sadly had much higher death rates (54% vs 31%) within 90 days. The findings suggest that certain patient characteristics and fungal species types may help identify those at higher risk of persistent infections.

Research Keyword: antifungal resistance